Notice of Results and Presentations

RNS Number : 6738Y

Diaceutics PLC

08 September 2022

 

8 September 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Notice of Results and Presentations

Diaceutics PLC, (AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its proprietary DXRX platform to the precision medicine market, confirms that it expects to announce its unaudited interim results for the six months ended 30 June 2022 on Tuesday, 27 September 2022.

Analyst Presentation

A webinar presentation for analysts will be held at 11 a.m. on Tuesday, 27 September 2022. Analysts wishing to attend should register their interest in advance with [e-mail].

Investor Presentation

Peter Keeling, CEO, Nick Roberts, CFO, and Ryan Keeling, CIO, will provide a live presentation relating to the Company's results via the Investor Meet Company platform on Wednesday, 28 September 2022 at 1 p.m.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 a.m. the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Diaceutics via: https://www.investormeetcompany.com/diaceutics-plc/register-investor

Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.

Enquiries:

Diaceutics PLC
Nick Roberts, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: [phone]
Caroline Forde	[e-mail]
Kieran Breheny
Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.

 

END

 

 

MSCLRMFTMTBMBJT